Breastfeeding Tied to Reduced Childhood Leukemia Risk
(MedPage Today) -- Longer duration of exclusive breastfeeding was associated with a reduced risk of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to results from a Danish population-based cohort study. Compared with... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2024 Category: Hematology Source Type: news

FDA Approves New Frontline Regimen for Aggressive ALL
(MedPage Today) -- The FDA granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in previously untreated adults, the agency announced this... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2024 Category: American Health Source Type: news

FDA Approves Ponatinib for Upfront Ph+ ALL FDA Approves Ponatinib for Upfront Ph+ ALL
This is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 20, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy f (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Efficacy was... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 6, 2024 Category: Drugs & Pharmacology Source Type: news

Development of CAR-T Cells for T-ALL Targeting CCR9, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news

Risk for Cancer Increased for Relatives of Patients With Leukemia
THURSDAY, Jan. 18, 2024 -- Relatives of patients with myelodysplastic neoplasia (MDS), acute myeloid leukemia (AML), or acute lymphoblastic leukemia (ALL) have an increased risk for cancer, according to a study published in the February issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2024 Category: Pharmaceuticals Source Type: news

What Prompts a Post-Childhood'Survival Cliff' in ALL? What Prompts a Post-Childhood'Survival Cliff' in ALL?
Experts explore why children with acute lymphoblastic leukemia fare well with current treatment options, while adolescents and younger adults still face high mortality rates.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Advances in Acute Lymphoblastic Leukemia From ASH 2023 Advances in Acute Lymphoblastic Leukemia From ASH 2023
Chemotherapy-free regimens in Philadelphia chromosome –positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news

Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL
(MedPage Today) -- Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the phase III randomized PREVAPIX... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2023 Category: Cardiology Source Type: news

Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news

Children With Down Syndrome More Vulnerable to Leukemia
WEDNESDAY, Nov. 1, 2023 -- While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as much.These young people are at increased risk for acute lymphoblastic leukemia (ALL) and have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 1, 2023 Category: General Medicine Source Type: news

Niche Interactions Lock Down Leukemia Cells
Researchers unravel the mystery of epithelial to mesenchymal transition in acute lymphoblastic leukemia with co-culture techniques, CRISPR-screening, and RNA sequencing. (Source: The Scientist)
Source: The Scientist - September 24, 2023 Category: Science Tags: News News & Opinion Source Type: news

Leukemia With IKZF ₁ Deletion Benefits From Prolonged Maintenance Therapy
MONDAY, July 31, 2023 -- For children with acute lymphoblastic leukemia (ALL), cases with IKZF ₁ deletion (IKZF₁del) benefit from prolonged maintenance therapy, according to a study published online July 17 in the Journal of Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2023 Category: Pharmaceuticals Source Type: news